0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > PD-1 > PD1-H52H6

Human PD-1 / PDCD1 Full Length Protein, His Tag

  • Synonym
    PDCD1,PD1,CD279,SLEB2
  • Source
    Human PD-1 Full Length, His Tag (PD1-H52H6) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Leu 288 (Accession # Q15116-1).
    Predicted N-terminus: Leu 25
  • Molecular Characterization
    Online(Leu 25 - Leu 288) Q15116-1

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 30.7 kDa. The protein migrates as 40-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >80% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM NaCl, pH8.0 with detergent. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) SDS-PAGE gel

Human PD-1 Full Length, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 80%.

Bioactivity-ELISA
Human PD-1 Full Length, His TagHuman PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) ELISA bioactivity

Immobilized Human PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) at 0.2 μg/mL (100 μL/well) can bind Nivolumab with a linear range of 0.4-3 ng/mL (QC tested).

Human PD-1 Full Length, His TagHuman PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) ELISA bioactivity

Serial dilutions of nivolumab were added into Human PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) : Human PD-L1, Mouse IgG1 Fc Tag, low endotoxin (Cat. No. PD1-H52A3) binding reactions. The half maximal inhibitory concentration (IC50) is 0.14891 (QC tested).

Human PD-1 Full Length, His TagHuman PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) ELISA bioactivity

Immobilized Human PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) at 0.2 μg/mL (100 μL/well) can bind Human PD-L1, Mouse IgG1 Fc Tag, low endotoxin (Cat. No. PD1-H52A3) with a linear range of 0.01-0.313 μg/mL (Routinely tested).

Human PD-1 Full Length, His TagHuman PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) ELISA bioactivity

Immobilized Human PD-1 Full Length, His Tag (Cat. No. PD1-H52H6) at 0.2 μg/mL (100 μL/well) can bind Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5) with a linear range of 0.5-8 ng/mL (Routinely tested).

  • Background
    Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $540.00

Price(USD) : $4500.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:8 Details
  • Number of Drugs in Clinical Trials:73 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop